Nervianos Aurora kinase effective and safe in Phase I

Data presented at the EORTC-NCI-AACR Symposium show Nerviano’s Aurora kinase inhibitor PHA 739358 to demonstrate good tolerability early signs of efficacy

Millennium present data on kinase programs at EORTC-NCI-AACR meeting

Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs:
MLN8237 – Aurora A  – Phase II trials expected in late 2008/early 2009
TAK-285 – EGFR/HER dual kinase  -  Demonstrated good target specificity, pharmacokinetics and distribution and efficacy in EGFR- and HER2-expressing xenograft models
TAK-593 -VEGF/PDGF – Preclinical data show potent pseudo-irreversibility [...]

EntreMeds Aurora A inhibitor ENMD-2076 effective in vivo

Data presented at the EORTC-NCI-AACR Annual Meeting show EntreMed’ Aurora A kinase inhibitor ENMD-2076 to demonstrate strong antitumor effects in a xenograft model of human colon cancer.

Vorinostat enhances MK-0457 activity in AML/CML

Vorinostat has been found to enhance the activity of Aurora kinase inhibitor MK-0457 (VX-680) on cultured human (HL-60, OCI-AML3, and K562) and primary acute myelogenous leukemia (AML) and chronic myelogenous leukemia (CML) cells

Cyclacel refocuses on non kinase projects

Cyclacel to focus resources on the advancement of its lead drug, sapacitabine. Workforce to be reduced by 28 employees (34% of total staff); Cambridge facility to be closed
It has not yet been decided if the company will further development CDK inhibitor Seliciclib or Aurora kinase inhibitor CYC116

Aurora Kinase inhibitor MK-0457 inhbits Ovarian Cancer Growth in mouse model

MK-0457 significantly reduced the proliferation of ovarian cancer cells, alone and in combination with docetaxel, in an orthotopic mouse model

Telik report progress with VEGFR/Aurora inhibitor program

Telik have announced that the lead compounds of its Aurora kinase/VEGFR dual inhibitor program have met a significant development milestone. A lead candidate is being selected, and assuming successful completion of preclinical studies, a Phase 1 clinical study may be initiated.

EntreMed partner with JSB for Aurora Kinase Program

EntreMed have partnered with JSB-Partners to enhance business development and partnering activities for its lead Aurora A/angiogenesis kinase inhibitor, ENMD-2076.

Sunesis publish information on discovery of Aurora kinase inhibitor

Sunesis have published  data on an Aurora kinase inhibitor

Genentech/Roche publish synthesis of Aurora Kinase inhbitor AKI-001

Genentech and Roche have published preclinical data on a new Aurora Kinase inhibitor AKI-001